Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Fig. 1

Sensitivity of SW780 (A-D) and RT4 (E–H) parental (PAR) and FGFR inhibitor resistant cell lines (SW780-RS, SW780-RD, RT4-RS, RT4-RD) to BGJ398 (A, E), erdafitinib (B, F), TAS-120 (C, G) and trametinib (D, H). Cells were treated with BGJ398, erdafitinib, TAS-120 or trametinib for 96 h and cell viability determined using the Cell Titre-Glo assay. Values shown are mean ± SEM of a representative experiment performed in triplicate

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us